Literature DB >> 12818223

Primary cutaneous lymphomas: a review with current treatment options.

Christiane Querfeld1, Joan Guitart, Timothy M Kuzel, Steven T Rosen.   

Abstract

Primary cutaneous T- and B-cell lymphomas are a heterogenous group of diseases with varied clinical presentations and prognosis. The use of new molecular, histological, and clinical criteria have enhanced the recognition of primary cutaneous T- and B-cell lymphomas. Compared to their nodal counterpart they have a different clinical behavior and therefore require a different treatment approach. Independent predictive factors identified clinically, histologically, and by immunopheno- and immunogenotyping are essential to assess the appropriate treatment for each subtype. The European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Study Group provide a classification of cutaneous lymphomas taking into account of the histological and molecular features. Based on this classification we will provide a summary of the current medical literature in diagnosis, treatment, and prognosis for primary cutaneous lymphomas with emphasis on new treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12818223     DOI: 10.1016/s0268-960x(03)00004-3

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  3 in total

1.  Primary cutaneous B-cell lymphoma: Role of surgery.

Authors:  Sam Parbhakar; Arianna Dal Cin
Journal:  Can J Plast Surg       Date:  2011

2.  Identification of p38β as a therapeutic target for the treatment of Sézary syndrome.

Authors:  Meghan Bliss-Moreau; Cristian Coarfa; Preethi H Gunaratne; Joan Guitart; Nancy L Krett; Steven T Rosen
Journal:  J Invest Dermatol       Date:  2014-08-22       Impact factor: 8.551

3.  Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma.

Authors:  Fani Karagianni; Christina Piperi; Berta Casar; Dalia de la Fuente-Vivas; Rocío García-Gómez; Kyriaki Lampadaki; Vasiliki Pappa; Evangelia Papadavid
Journal:  Cancers (Basel)       Date:  2022-02-20       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.